Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data.
Guerra Veloz MF, Belvis Jiménez M, Valdes Delgado T, Castro Laria L, Maldonado Pérez B, Perea Amarillo R, Merino Bohórquez V, Caunedo Álvarez Á, Vilches Arenas Á, Argüelles-Arias F. Guerra Veloz MF, et al. Among authors: castro laria l. Therap Adv Gastroenterol. 2019 Jun 18;12:1756284819858052. doi: 10.1177/1756284819858052. eCollection 2019. Therap Adv Gastroenterol. 2019. PMID: 31258621 Free PMC article.
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
Argüelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado Pérez B, Chaaro Benallal D, Benítez Roldán A, Merino V, Ramirez G, Calleja-Hernández MA, Caunedo Álvarez A, Romero Gómez M. Argüelles-Arias F, et al. Among authors: castro laria l. Eur J Gastroenterol Hepatol. 2017 Nov;29(11):1290-1295. doi: 10.1097/MEG.0000000000000953. Eur J Gastroenterol Hepatol. 2017. PMID: 28902041 Free PMC article.
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months.
Guerra Veloz MF, Vázquez Morón JM, Belvis Jiménez M, Pallarés Manrique H, Valdés Delgado T, Castro Laria L, Maldonado Pérez B, Benítez Roldán A, Perea Amarillo R, Merino V, Caunedo Álvarez Á, Argüelles Arias F. Guerra Veloz MF, et al. Among authors: castro laria l. Rev Esp Enferm Dig. 2018 Sep;110(9):564-570. doi: 10.17235/reed.2018.5368/2017. Rev Esp Enferm Dig. 2018. PMID: 29893581 Free article.
Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.
Guerra Veloz MF, Argüelles-Arias F, Castro Laria L, Maldonado Pérez B, Benítez Roldan A, Perea Amarillo R, Merino Bohórquez V, Calleja MA, Caunedo Álvarez Á, Vilches Arenas Á. Guerra Veloz MF, et al. Among authors: castro laria l. World J Gastroenterol. 2018 Dec 14;24(46):5288-5296. doi: 10.3748/wjg.v24.i46.5288. World J Gastroenterol. 2018. PMID: 30581277 Free PMC article.
Cut-off ranges of infliximab serum levels in Crohn's disease in the clinical practice.
Valdés Delgado T, Guerra Veloz MF, Castro Laria L, Maldonado Pérez B, Perea Amarillo R, Merino Bohórquez V, Sáez A, Caunedo Álvarez Á, Argüelles Arias F. Valdés Delgado T, et al. Among authors: castro laria l. Rev Esp Enferm Dig. 2020 Oct;112(10):756-761. doi: 10.17235/reed.2020.6539/2019. Rev Esp Enferm Dig. 2020. PMID: 32954770 Free article.
Ustekinumab in Crohn's disease: real-world outcomes and predictors of response.
Lorenzo González L, Valdés Delgado T, Vázquez Morón JM, Castro Laria L, Leo Carnerero E, Maldonado Pérez MB, Sánchez Capilla D, Pallarés Manrique H, Sáez Díaz A, Argüelles Arias F; Grupo de Enfermedad Inflamatoria de Andalucía. Lorenzo González L, et al. Among authors: castro laria l. Rev Esp Enferm Dig. 2022 May;114(5):272-279. doi: 10.17235/reed.2020.7352/2020. Rev Esp Enferm Dig. 2022. PMID: 33393332 Free article.
Switch to subcutaneous infliximab during the SARS-CoV-2 pandemic: preliminary results.
Argüelles-Arias F, Fernández Álvarez P, Castro Laria L, Maldonado Pérez B, Belvis Jiménez M, Merino-Bohórquez V, Caunedo Álvarez Á, Calleja Hernández MÁ. Argüelles-Arias F, et al. Among authors: castro laria l. Rev Esp Enferm Dig. 2022 Feb;114(2):118-119. doi: 10.17235/reed.2021.8320/2021. Rev Esp Enferm Dig. 2022. PMID: 34517718 Free article.
38 results